DAY 2: Saturday, June 4
Welcome back to Today@ADA – a round-up of our picks from the second day at the American Diabetes Association’s 82nd Scientific Sessions, taking place in person in New Orleans, and on-demand on the virtual portal.
Today’s interview is with Ania M. Jastreboff from Yale University School of Medicine, who presented primary and secondary outcomes from the SURMOUNT-1 study. The findings suggest the magnitude of weight loss achieved with tirzepatide places it within the range of surgical interventions. Over 72 weeks, once-weekly tirzepatide resulted in substantial weight reduction over and above that achieved with lifestyle intervention in people with obesity. This well-attended session coincided with the publication of the NEJM paper, but you can get the highlights directly from us!
We also interviewed Alan Delamater from the University of Miami Miller School of Medicine, who gave the Richard R. Rubin Award Lecture. Click through to listen to him discussing his talk entitled “Forty Years of Behavioral Diabetes Research—A Personal Journey”.
The weekend was incredibly busy, with a real buzz throughout the sessions, and in the exhibits and poster halls. For my pick of Day 2, we start with the results of the SURMOUNT-1 trial, presented by Ania M. Jastreboff, from Yale University School of Medicine. We then continue with William Cefalu, from the National Institute of Diabetes and Digestive and Kidney Diseases, and his presentation on precision medicine in diabetes, where he looked at ongoing research, and discussed the potential next steps.
After that, I bring you highlights from the Kaiser Permanente Center for Health Research, presented by Stephanie Fitzpatrick in the NIDDK Early Career Investigator Symposium. My summary picks out a couple of key points Stephanie delivered around novel diabetes prevention and treatment approaches in under-served and diverse populations and settings.
Last but by no means least for Day 2, Kirk Habegger, part of the faculty at the University of Alabama at Birmingham, presented on glucagon receptor agonism and insulin sensitivity.
I hope you are enjoying the congress and making the most of the wealth of resources available to you. Connect with us on social media to get more news and announcements, and we’ll be back soon with the update from Day 3.
Dana Dabelea, MD, PhD
ADA 2022 Highlights Editor
Denver, CO, USA